T. Noesslinger

发表

Comorbidity as Prognostic Variable in MDS: Comparative Evaluation of the HCT-CI and CCI in a Core Data Set of 582 Patients of the Austrian MDS Platform.

P. Valent, M. Pfeilstöcker, W. Sperr, 2008 .

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

R. Greil, M. Ziepert, W. Stevens, 2012 .

A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1

R. Greil, S. Machherndl-Spandl, P. Valent, 2018, Leukemia & lymphoma.

New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.

C. Steidl, C. Fonatsch, P. Valent, 2006 .

New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics

C. Steidl, F. Solé, M. Slovak, 2008 .

12 Updated cytogenetic risk features in MDS – present state

C. Steidl, F. Solé, P. Greenberg, 2009 .

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

G. Superti-Furga, U. Jaeger, B. Snijder, 2021, Cancer discovery.

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

C. Steidl, L. Arenillas, F. Solé, 2011, Leukemia.

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

U. Jaeger, M. Hallek, G. Juliusson, 2021, Blood.

Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes

P. Valent, W. Sperr, U. Germing, 2010, Cancer.

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

F. Bosch, H. Döhner, M. Hallek, 2016 .

High‐dose Bendamustine‐EAM followed by autologous stem cell rescue results in long‐term remission rates in lymphoma patients, without renal toxicity

F. Keil, E. Koller, A. Boehm, 2018, European journal of haematology.

Cytogenetic Risk Features in MDS-Update and Present State.

C. Steidl, F. Solé, M. L. Beau, 2009 .

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

M. Hallek, G. Juliusson, S. Stilgenbauer, 2023, Blood.

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Lauren C. Chong, A. Rosenwald, W. Chan, 2018, Blood.

Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)

F. Bosch, H. Döhner, M. Pfreundschuh, 2014 .